Xstrahl to Spotlight Superficial and Orthovoltage Radiotherapy Solutions for Skin Cancer and Selective Benign Conditions at AAPM 2024 in Los Angeles
Xstrahl will also preview new internal eye shield portfolio to protect patients’ lenses during treatment
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate the Xstrahl 200, a modern orthovoltage radiotherapy solution for treating superficial lesions, skin cancers, and selective benign conditions at the 66th Annual Meeting & Exhibition of the American Association of Physicists in Medicine (AAPM) in Los Angeles, CA, from July 21-25, 2024, at booth 518.
AAPM 2024 attendees will learn about the Xstrahl 200 X-ray system, a versatile orthovoltage radiotherapy solution for treating superficial lesions, skin cancers, and benign conditions and also for delivering palliative care. It delivers both superficial treatments and treatments at depth by combining the capability of orthovoltage X-ray systems with the traditional ease-of-use of superficial radiation therapy. Xstrahl 200 expands treatment options for benign indications, such as keloid scarring, Ledderhose disease, and Dupuytren’s disease, and is an excellent complement to a linear accelerator to add treatment capacity at a low cost.
“We look forward to discussing the expansion of radiation therapy to patient care with the attendees at AAPM 2024,” stated Adrian Treverton, CEO of Xstrahl, Inc. “The Xstrahl 200 is a great addition to a linac-based cancer therapy program because it helps improve the level of patient care, treatment capacity, and the range of treatment options for patients quickly, simply, and affordably. It provides excellent maneuverability to help support the delivery of low-energy radiation treatments all over the body, which is especially important for patients with mobility issues,” Treverton added.
Visit the Xstrahl booth where we will showcase our new internal eye shields at AAPM 2024. Internal eye shields are a simple yet effective solution to protect the patient’s lenses during superficial and orthovoltage radiation therapy treatments. CE marked and available in four sizes, the internal eye shields are designed to be used for applications up to and including 120kV, the typical maximum energy used to treat NMSC near the eye and its sensitive structures.
Xstrahl will also feature Radiant™ Aura at AAPM 2024. Radiant Aura is a low-dose, X-ray based, dual modality radiation therapy that offers both non-invasive electronic brachytherapy (eBt) and superficial radiation therapy (SRT) for NMSC and keloid scarring.
If you are attending AAPM 2024 and would like to join our VIP list for private events, please reach out to Asad Khan at asadkhan@xstrahl.com.
Visit Xstrahl at AAPM 2024 at booth 518, at the Los Angeles Convention Center, Los Angeles, CA from July 21-25, 2024.
About Xstrahl
Xstrahl is a medical technology company that designs radiation delivery devices to support clinical teams and cancer researchers. For more than 25 years, Xstrahl has been shaping the development of superficial and orthovoltage radiation therapy and advancing preclinical radiation research. Xstrahl systems are in operation at more than 700 treatment and research facilities worldwide.
To learn more about Xstrahl at AAPM 2024, visit www.com/xstrahl.com/aapm-2024/
To learn more about all Xstrahl clinical and research systems, visit www.xstrahl.com
To learn more about Xstrahl eye shields, visit www.com/eye-shield-webinar
To learn more about Radiant Aura, visit www.radiant-therapy.com
